Shrinath Barathan, M.D.
Professional Experience
| Clinical Chief of Nephrology 2013–Present | Cedars Sinai Medical Center, Los Angeles. |
| Assistant Professor of Medicine 2011–Present. | David Geffen School of Medicine, UCLA. |
| Clinical Instructor 2004-2011. | David Geffen School of Medicine, UCLA. |
| Attending Staff Physician 2003–Present. | Cedars Sinai Medical Center, Los Angeles. |
| Preceptor 2012–Present. | School of Nursing. California State University, Los Angeles. |
| Partner. 2003–Present. | Tower Nephrology Medical Group, Los Angeles. |
| Assistant Medical Director. | 2009–Present. Crescent Heights Dialysis Center. Los Angeles. |
Committees At Cedars Sinai Medical Center
| 2013–Present | Department of Medicine Performance Improvement Committee |
| 2008 - Present | Pharmacy and Therapeutics Commitee |
| 2010 - Present | Joint Dialysis Oversight Committee |
| 2010 - Present | Best Practices for Continuous Renal Replacement Therapy Committee |
| 2010 - Present | Cardiac Surgical ICU Innovation Project |
| 2010 - Present | Vaptan Task Force |
| 2011-Present | Code Sepsis Committee - Clinical Team to device protocols for septic patients |
| 2011-Present | Electronic Medical Record. CS Link Nephrology Task Force |
Education And Training
| College | BS in Chemistry. Presidency College, Madras University, India. 1983-1986. |
| Medical | MD. 1987-1993. National Pirogov Memorial Medical University, Vinnytsya. |
| Residency | Internal Medicine, 1997-2000. MetroHealth Medical Center, The Rammelkamp Center for Education and Research, MetroHealth Medical Center. Case Western Reverse University, Cleveland, Ohio. |
| Fellowship | Nephrology, 2000-2003. University Hospitals, MetroHealth Medical Center, VA Medical Center, Cleveland, Ohio. Case Western Reserve University. |
Awards And Certifications
| 1987 | Fully funded scholarship to medical school sponsored by Governments of India and USSR. |
| 1993 | Certified Teacher of Russian Language. |
| 2000 | Diplomate in Internal Medicine, American Board of Internal Medicine. |
| 2000 | ACLS Provider |
| 2000 | BLS Provider |
| 2003 | Board Certified, Subspecialty Board in Nephrology, American Board of Internal Medicine. |
Licensures
| Medical | California State Medical Board |
Other Services
President. 1986-1987. Foreign Students Association. National Pirogov Memorial Medical University, Vinnytsya. Ukraine.
Languages Spoken
English, Russian, Malayalam and Tamil
Scientific Presentations
- Senior Resident Grand Rounds, 2000, "Progression of Chronic Renal Disease", Metro Health Medical Center, Cleveland, OH
- Research Days 2000, "Comparison of mRNA kidney expression profiles generated by Serial Analysis of Gene Expression (SAGE) to identify candidate nephropathy genes in C57BL/6-Os/ + Versus ROP-Os/ + mice", Rammelkamp Center for Education and Research, MetroHealth Medical Center, Cleveland OH.
- Research Days 2002, "The cell guidance molecule neuropilin-2 is under expressed in podocytes of sclerosis-prone ROP-Os/+, but not C57Bl/6-Os/+mice", Rammelkamp Center for Education and Research, MetroHealth Medical Center, Cleveland, OH.
- Journal Club, 2002, "Treatment of Lupus Nephritis", University Hospital of Cleveland, Cleveland, OH.
- Journal Club, 2003. "Major Outcomes in High-Risk Hypertensive Patients Randomized Patients Randomized to ACE Inhibitor or Calcium Channel Blocker vs. Diuretic" The ALLHAT Trial. University Hospitals of Cleveland, Cleveland, OH.
Clinical Study Location
-
Tower Nephrology Medical Group, 8635 W. 3RD ST #485W Los Angeles, CA 90048
Da Vita of Beverly Hills, 50 N. La Cienega blvd. #300 Beverly hills, CA 90211
Da Vita of Crescent Heights, 8151 Beverly blvd Los Angeles, CA 90048
Clinical Studies
2013 ICH Good Clinical Practice for Clinical Trial Sites (Certificates)
| Sub-Investigator | 2014 | Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease (CDK) Patients on Hemodialysis |
| Sub-Investigator | 2014 | A Multicenter Single-arm Extention Study to Describe the Long- term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis |
| Sub-Investigator | 2013 | A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis. |
| Sub-Investigator | 2013 | ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia. |
| Sub-Investigator | 2013 | Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease. |
| Sub-Investigator | 2013 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137 |
| Sub-Investigator | 2012 | A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy |
| Sub-Investigator | 2011 | A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis |
| Sub-Investigator | 2011 | Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon) |
| Sub-Investigator | 2011 | A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study |
2010 GCP Certified by the National Cancer Institute
| Sub-Investigator | 2010 | A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease. |
| Sub-Investigator | 2010 | Study to evaluate the improved management of iPTH with paracalcitol- centered therapy vs. cinacalcet therapy with low-dose vitamin d in hemodialysis patients with secondary hyperparathyroidism. |
| Sub-Investigator | 2009 | A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor. |
| Sub-Investigator | 2008 | Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia. |
| Sub-Investigator | 2007 | A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin |
| Sub-Investigator | 2007 | Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis |
| Sub-Investigator | 2007 | A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®) |
| Sub-Investigator | 2007 | A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections. |
| Sub-Investigator | 2007 | Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis. |
| Sub-Investigator | 2007 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease. |
| Sub-Investigator | 2007 | A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease |
| Sub-Investigator | 2007 | An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency |
| Sub-Investigator | 2006 | A randomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy. |
| Sub-Investigator | 2006 | Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events. |
| Sub-Investigator | 2006 | A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis. |
| Sub-Investigator | 2005 | An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease. |
| Sub-Investigator | 2004 | Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis. |
| Sub-Investigator | 2004 | Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis. |
Original Contributions
-
Identification of nephropathy candidate genes by comparing sclerosis-prone and sclerosis-resistant mouse strain kidney transcriptomes. El-Meanawy A, Schelling JR, Iyengar SK, Hayden P, Barathan S, Goddard K, Pozuelo F, Elashi E, Nair V, Kretzler M, Sedor JR. BMC Nephrol. 2012 Jul 19;13:61. doi: 10.1186/1471-2369-13-61.
Serial analysis of gene expression. El-Meanawy MA, Barathan S, Hayden PS, Iyengar SK, Schelling JR, Sedor JR. Methods Mol Med. 2003;86:257-74.
Generation of kidney transcriptomes using serial analysis of gene expression. Schelling JR, El-Meanawy MA, Barathan S, Dodig T, Iyengar SK, Sedor JR. Exp Nephrol. 2002;10(2):82-92.
Reviews
- M.A. El-Meanawy, J.R. Schelling, S. Barathan, S.K. Iyengar and J.R. Sedor. Serial analysis of gene
expression (SAGE). In: Methods in Molecular Medicine: Renal Disease. Guide to Technical Approaches.
M.S. Goligorsky, ed. The Humana Press, Totowa, NJ, in press 2002.
Abstracts
- Goddard KA, El-Meanawy A, Schelling JR, Elashi E, Barathan S., Konieczkowski M., Kamat S, Koepke S, Covie A, Sedor JR and Iyengar SK. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression (SAGE) to identify candidate nephropathy genes in C57BL/6Os/+ versus ROP-Os/+mice. Am J Hum Genet 67:1456T, 2000. El-Meanawy, A., J. Schelling, E. Elashi, S. Barathan, M. Konieczkowski, S. Kamaet, A. Koepke,
- K. Goddard, A. Covic, S Iyengar and J. Sedor. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression to identify candidate nephropathy genes in C57BL/6-Os/+ versus ROP-Os/+mice. J. Am Soc. Nephrol, 11:617A, 2000.
- J.R. Schelling, A. El-Meanawy, E. Elashi, S. Barathan, M. Konieczkowski, S. Kamat, A. koepke, K. Goddard, A. Covic, S.I. Iyanar and J.R. sedor. Comparison of mRNA kidney expression profiles generated by serial analysis of gene expression (SAGE) to identify candidate nephropathy genes in C57BL/6-Os/+ versus ROP-Os/+mice. Nephrology, Dialysis and Transplantation 15:A34, 2000.
- El-Meanawy, S. Barathen, M. Konieczkoski, E. Elashi A. Covic, T. Dodig, S. Khan, A. Koepke, F. Pozuelo, K. Goddard, S. Iyangar, J.R. Schelling and J.R. Sedor. Gene expression profiles generated by serial analysis of gene expression (SAGE) identify candidate molecular pathways regulating progressive glomerulosclerosis. Nephrology, Dialysis and Transplantation 16:A38,2001.
- El-Meanawy, M.A., S. Barathan, T. Dodig, E. Elashi, K. Goddard, S. K. Iyengar, J.R. Schelling and John R. Sedor. Kidney transcriptome profiles generated by serial analysis of gene expression identify candidate molecular pathways regulating progressive glomerulosclerosis. J. Am. Soc. Nephrol. 12:617A, 2001.
- Barathan, S., M. Konieczkowski, A. El-Meanawy*, S. Khan, B. Wang, T. Dodig, S.K. Iyengar, J.R. Schelling and J.R. Sedor. Expression analysis demonstrated the cell guidance signal neuropilin 2b (nrp2) is reduced in sclerosis-prone Rop-Os/+ but not sclerosis-resistant C57-Os/+ mouse kidneys. J. Am. Soc. Nephrol. 12:617A, 2001.
- P. Hayden, M.A. El-Meanawy, S. Barathan, G. Jarad, M. Srichai, M. Konieczkowski, S. Iyengar, J.R. Schelling, J.R. Sedor. Serial Analysis of Gene expression (SAGE)- Generated Libraried from Kidneys of Sclerosis-Prone and Sclerosis-Resistant Mice Identify aRenal Disease-Associated Replicon. J. Am Soc. Nephrol. 13:118A, 2002.
- S. Barathan, S. Iyengar, L. Bruggeman, P. Mundel, M. El-Meanawy, M. Konieczkowski, J. Schelling, J. Sedor. The Cell Guidance Molecule Neuropilin-2 Is Underexpressed in Podocytes of Sclerosis-Prone ROP-Os/+, but Not C57B1/6-Os/+Mice. J. Am Soc. Nephrol.13:124A, 2002.
- M.B. Srichai, M. Konieczkowski, S. Barathan, S. Khan, P. Mundel, S. Lee, L. Bruggeman, J.R. Schelling, J.R. Sedor. A Novel WT1 Co-Regulator That Shuttles between Nucleus and Plasma Membrane, J. Am. Soc. Nephrol. 13:16A, 2001